Since the approval of ipilimumab in 2011 for metastatic melanoma, immune checkpoint inhibitors (ICI) have shifted the treatment paradigm in oncology. Now increasingly indicated as first-line treatment of certain metastatic cancers, ICIs can trigger deep, durable responses and offer significant survival benefit. However, the majority of patients do not respond and many epeirence immune-related adverse events (irAEs).
As researchers seek to improve the efficacy and safety of ICIs and expand the application of these immunotherapies to broader patient populations, a critical area of study is dosing optimization. The goal of dosing optimization is to maximize therapeutic efficacy and access while minimizing toxicity and cost.
read this guide
By submitting your information to us through this webform, your business details will be added to our database. In accordance with our Privacy Notice, we may then contact you with marketing information about Premier Research that might be of interest to you. We will never sell your details to third parties. You can unsubscribe from marketing communications at any time.